Christopher Lee Boyer

US Patent:

20020147175, Oct 10, 2002

Filed:

Nov 16, 2001

Appl. No.:

09/990799

Inventors:

H. Shepard - Encinitas CA, US
Christopher Boyer - San Diego CA, US

International Classification:

A61K031/7064
A61K031/505
A61K031/519
A61K031/675

US Classification:

514/049000, 514/256000, 514/260100, 514/086000

Abstract:

This invention provides compositions containing an effective amount of a novel substrate compound that selectively inhibit the proliferation of hyperproliferative cells, for example, pathological cells that endogenously overexpress a target enzyme that confers resistance to biologic and chemotherapeutic agents and an effective amount of a nucleoside transport antagonistic agents. Further provided by this invention is a method for treating a subject by delivering to the subject the composition as described herein. The compositions of this invention may be used alone or in combination with other chemotherapeutics or alternative anti-cancer therapies such as radiation.

US Patent:

20030212037, Nov 13, 2003

Filed:

Dec 10, 2002

Appl. No.:

10/168722

Inventors:

Christopher Boyer - San Diego CA, US
David Lackey - San Diego CA, US

International Classification:

A61K031/7072
A61K031/56

US Classification:

514/050000, 514/171000

Abstract:

This invention provides methods for selectively killing a hyperproliferative cell by contacting the cell with the compound BVdU, its derivatives and pharmaceutically acceptable salts. Further provided by this invention is a method for treating a pathology in a subject characterized by pathological, hyperproliferative cells by administering to the subject an effective amount of the compound BVdU, its derivatives and pharmaceutically acceptable salts. The invention also provides a method for screening for potential therapeutic agents by contacting a neoplastic cell with the agent and with BVdU and performing an assay to detect inhibition of proliferation and cell killing. The invention also provides methods for selecting from among a patient population, patients that are likely to benefit from treatment with BVdU, by determining the level of endogenous, intracellular TK and TS. The invention also provides methods for sensitizing patients to the therapeutic effects of BVdU by treatment with substances that result in the increase in the levels of TK in hyperproliferative cells.

US Patent:

20050080035, Apr 14, 2005

Filed:

Sep 29, 2004

Appl. No.:

10/954797

Inventors:

Christopher Boyer - San Diego CA, US
David Lackey - San Diego CA, US

International Classification:

A61K031/7072

US Classification:

514049000

Abstract:

This invention provides methods for selectively killing a hyperproliferative cell by contacting the cell with the compound BVdU, its derivatives and pharmaceutically acceptable salts. Further provided by this invention is a method for treating a pathology in a subject characterized by pathological, hyperproliferative cells by administering to the subject an effective amount of the compound BVdU, its derivatives and pharmaceutically acceptable salts. The invention also provides a method for screening for potential therapeutic agents by contacting a nonplastic cell with the agent and with BVdU and performing an assay to detect inhibition of proliferation and cell killing. The invention also provides methods for selecting from among a patient population, patients that are likely to benefit from treatment with BVdU, by determining die level of endogenous, intracellular TK and TS. The invention also provides methods for sensitizing patients to the therapeutic effects of BVdU by treatment with substances that result in the increase in the levels of TK in hyperproliferative cells.